Overview

Clinical Trial to Investigate the Safety and Tolerability of EP395 in Patients With COPD

Status:
Not yet recruiting
Trial end date:
2023-08-31
Target enrollment:
Participant gender:
Summary
The aim of this clinical trial is to investigate the safety and tolerability of oral, once-daily EP395 administration in COPD patients for 12 weeks.
Phase:
Phase 2
Details
Lead Sponsor:
EpiEndo Pharmaceuticals
Collaborator:
FGK Clinical Research GmbH